Comparative assessment of five trials of universal HIV testing and treatment in sub-Saharan Africa-Reference-Cited by-同舟云学术

Comparative assessment of five trials of universal HIV testing and treatment in sub-Saharan Africa

Published:2018-01 Issue:1 Volume:21 Page:e25048
ISSN:1758-2652
Container-title:Journal of the International AIDS Society
language:en
Short-container-title:J Intern AIDS Soc

Author:

Perriat Delphine¹²³^ORCID,Balzer Laura⁴⁵^ORCID,Hayes Richard⁶,Lockman Shahin⁷⁸⁹,Walsh Fiona¹⁰,Ayles Helen¹¹¹²,Floyd Sian⁶,Havlir Diane⁴,Kamya Moses¹³,Lebelonyane Refeletswe¹⁴,Mills Lisa A¹⁵,Okello Velephi¹⁶,Petersen Maya¹⁷,Pillay Deenan³¹⁸,Sabapathy Kalpana⁶^ORCID,Wirth Kathleen¹⁸,Orne-Gliemann Joanna¹²³,Dabis François¹²³^ORCID,

Affiliation:

1. Inserm, Bordeaux Population Health Research Center, UMR 1219; University Bordeaux; Bordeaux France

2. Inserm, ISPED; Bordeaux Population Health Research Center, UMR 1219; Bordeaux France

3. Africa Health Research Institute; Somkhele KwaZulu-Natal South Africa (ANRS TasP trial)

4. University of California San Francisco; San Francisco CA USA (SEARCH trial)

5. University of Massachusetts Amherst; Amherst MA USA

6. Department of Infectious Disease Epidemiology; London School of Hygiene & Tropical Medicine; London United Kingdom (PopART trial)

7. Harvard School of Public Health; Boston MA USA (BCPP trial)

8. Botswana Harvard AIDS Institute Partnership; Gaborone Botswana (BCPP trial)

9. Brigham and Women's Hospital; Boston MA USA (BCPP trial)

10. Clinton Health Access Initiative; Boston MA USA (MaxART trial)

11. Department of Clinical Research; London School of Hygiene & Tropical Medicine; London United Kingdom (PopART trial)

12. Zambart; Lusaka Zambia

13. Makerere University School of Medicine; Uganda (SEARCH trial)

14. Ministry of Health, Republic of Botswana; Gaborone Botswana (BCPP)

15. Centers for Disease Control; Gaborone Botswana (BCPP trial)

16. Ministry of Health, Kingdom of Swaziland; Mbabane Swaziland (MaxART trial)

17. University of California Berkeley School of Public Health; Berkeley CA USA (SEARCH trial)

18. Department of Infection; University College London; London United Kingdom (ANRS TasP trial)

Funder

Bill and Melinda Gates Foundation

U.S. President’s Emergency Plan for AIDS Relief

Dutch Postcode Lottery

Embassy of the Kingdom of the Netherlands in Mozambique

British Colombia Centre of Excellence in Canada

Mylan

Doctors Without Borders

National Institute of Allergy and Infectious Diseases

National Institutes of Health

National Institute of Mental Health

Ministries of Health of Uganda and Kenya

World Health Organization

UNAIDS

World Bank Group

Global Fund to Fight AIDS, Tuberculosis and Malaria

Infectious Diseases Research Collaboration (IDRC)

Kenya Medical Research Institute (KEMRI)

Gilead Sciences

French National Institute of Health

Medical Research-French National Agency for AIDS

Viral Hepatitis Research (Inserm−ANRS)

Agence Nationale de Recherches sur le Sida et les Hépatites Virales

Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH

International Initiative for Impact Evaluation (3iE)

Merck

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Reference104 articles.

1. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group;Quinn;N Engl J Med,2000

2. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa;Tanser;Science,2013

3. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model;Granich;Lancet,2009

4. Granich RM Gupta S Samb B Donaldson E Fisher K Antiretroviral Treatment for Prevention of HIV and Tuberculosis: 2013 update on current and planned research efforts 2014 http://www.avac.org/sites/default/files/resource-files/ART%20for%20prevention%20study%20update%20report%20March%202014.pdf

5. Les personnes séropositives ne souffrant d'aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle;Vernazza;Bull Méd Suisses,2008

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunologic, virologic and drug resistance outcomes in an HIV-infected prospective cohort on treatment in South Africa;PLOS ONE;2024-08-26

2. Assessing Direct and Spillover Effects of Intervention Packages in Network-randomized Studies;Epidemiology;2024-05-06

3. Changes in access to viral load testing, incidence rates of viral load suppression and rebound following the introduction of the ‘universal test and treat’ guidelines in Cameroon: A retrospective follow-up analysis;PLOS Global Public Health;2024-04-16

4. Estimating the Cost-Effectiveness of HIV Self-Testing in the United States Using Net Benefit Regression;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-02-01

5. Temporal dynamics and drivers of durable HIV viral load suppression and persistent high‐ and low‐level viraemia during Universal Test and Treat scale‐up in Uganda: a population‐based study;Journal of the International AIDS Society;2024-02